SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors digest recent financial results, with community chatter focused on valuation concerns after a significant run-up. While some bulls remain optimistic about the company's AI prospects and long-term growth, bears point to a high P/E ratio and potential market correction. News of a major investor taking a short position is also contributing to the conversation.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to significant trading volume and speculation around potential acquisitions and earnings. Community discussions revolve around Michael Burry's call option positions and Pfizer's ongoing legal battles with Novo Nordisk over Metsera. Some traders anticipate a breakout post-earnings, while others remain skeptical, citing past performance and heavy debt.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending due to positive earnings reports and increasing discussion around its partnerships, especially regarding autonomous vehicle technology with companies like NVIDIA and Lucid. The community is actively discussing the potential for robotaxis and the impact on Uber's future profitability, though some express frustration with the stock's price action despite positive news. Some traders are wary of a potential downside setup, while others are aggressively buying calls in anticipation of a significant move upwards leading up to earnings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a confirmatory trial and its potential impact on existing PMO therapies, which are facing scrutiny, while Elevidys sales remain a key focus. The community is weighing the implications for future revenue and potential FDA actions, with some speculating about a possible Roche buyout amid the uncertainty. Discussions also involve management's handling of recent data releases and their overall strategy.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining attention, particularly within communities focused on the Solana ecosystem, with some users expressing bullish sentiment while others discuss challenges. The community emphasizes a shared vision and encourages building together, fostering a sense of unity despite market conditions.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst community debates about its long-term potential and current market performance, with some expressing concerns about its ranking and past hype, while others remain hopeful for future gains related to data management and AI. Discussions include technical analysis with an emphasis on key resistance levels, while some traders discuss longing or shorting the token. The community speculates on potential market catalysts, including developments with Janction and the J-Credit system.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions about its upcoming earnings report and potential partnerships, particularly with Novo Nordisk ($NVO). Community members are debating the company's growth prospects, with some highlighting its expansion into new markets and others expressing concern over profitability and insider selling. Analyst ratings are mixed, with some firms setting high price targets while others have a more cautious outlook.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines ($LUNR) is trending due to its acquisition of Lanteris Space Systems, a move seen as transforming the company into a major competitor in the aerospace and defense sector. The community is discussing the combined revenue, backlog, and expanded capabilities into new mission types and government programs. This acquisition is viewed as a shift in the valuation story, with some anticipating a rotation into smaller, innovative players in the space industry.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending after OpenAI announced a partnership to enable in-app purchases within ChatGPT, potentially driving more traffic to SHOP merchants. Community members are discussing the implications for e-commerce and SHOP's competitive positioning, with some highlighting the company's growth prospects and others questioning its valuation. The stock is testing new 52-week highs as investors assess the impact of this development on Shopify's long-term growth and AI strategy.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is trending due to a mixed earnings report, beating EPS expectations but falling slightly short on revenue, sparking debate among investors about its valuation. While the company raised its 2025 adjusted EPS guidance and highlighted record revenue, community sentiment is divided, with some questioning the market's negative reaction and others pointing to potential overvaluation or broader market concerns. Community members are also discussing call/put walls and potential market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for Oct. 17th

GYRE, DAR and CRLBF have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2025.

Cannabis Stock CRLBF Gains 25% in a Month: Time to Buy, Sell or Hold?

CRLBF surges 25% this month on reform hopes, but revenue declines, margin pressure and stiff competition cloud its outlook.

Cresco Labs Inc. (CRLBF) Reports Q2 Loss, Lags Revenue Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -25.00% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Lags Q2 Earnings and Revenue Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -3.39% and -2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +7.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cannabis Operator CRLBF Plans California Exit: How to Play the Stock?

Cresco plans to exit California, citing tough market dynamics, as it sharpens focus on high-margin growth markets.

Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?

GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.

Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?

CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.

Cresco Labs Inc. (CRLBF) on Friday reported a decline in its first-quarter revenue while losses widened, sending shares down 8% in midday trading.The company, which makes branded cannabis products, <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250529949504/en/Cresco-Labs-Continues-Track-Record-of-Delivering-Strong-Operating-Cash-Flow">reported</a> revenue of $166 million for the three months through the end of March, down from the $184 million reported in the corresponding period of 2024.However, this surpassed an analyst estimate of $165 million, as per Finchat data.The Sunnyside dispensaries operator reported a net loss of $15 million for the quarter, compared to a loss of $2 million in the corresponding period of last year.Adjusted earnings before interest, taxes, depreciation, and amortization came in at $36 million, in line with an analyst estimate of $35.9 million, but below the $54 million reported in the first quarter (Q1) of 2024.The company ended the quarter with cash, cash equivalents, and restricted cash of $159 million, as well as senior secured term loan debt, net of discount and issuance costs, of $353 million. The company also had a mortgage loan, net of discount and issuance costs of $18 million.Cresco was initially slated to report earnings earlier this month, but postponed it to provide additional time to complete procedures for reviewing its first-quarter financial statements.On Stocktwits, retail sentiment around CRLBF rose from ‘neutral’ to ‘bullish’ territory while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_1_49_08_PM_png_4ee23c9749.webp" alt="CRLBF's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 30, 2025 | Source: Stocktwits" width="631" height="57"><figcaption>CRLBF's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed skepticism about the OTC counter, calling it ‘a cautionary tale.’<stembedurl>https://stocktwits.com/BobStillSizzlin/message/616337292</stembedurl>According to data from Koyfin, six of seven analysts covering the Cresco stock rate it ‘Buy’ or higher, while one rates it a ‘Hold’.<a href="https://stocktwits.com/symbol/CRLBF">CRLBF</a> is down by 34% this year and by about 66% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-jamie-dimon-enemy-within-china-potential-adversary/ch0uPM9RbuQ">Jamie Dimon Warns Of The Enemy Within, Says He’s Not As Worried About China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Cresco Labs is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cresco Labs’ Q1 Loss Widens, Revenue Declines: Retail Terms It A ‘Cautionary Tale’ For Investors

The Sunnyside dispensaries operator reported a net loss of $15 million for the quarter, compared to a loss of $2 million in the corresponding period of last year.

Equity

The Sunnyside dispensaries operator reported a net loss of $15 million for the quarter, compared to a loss of $2 million in the corresponding period of last year.


Trump Is Pushing to Supercharge the Marijuana Industry. 2 ‘Strong Buy’ Stocks to Buy

Wall Street sees triple-digit upside in AAWH and CRLBF as regulatory momentum builds.

Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.

Cresco Labs Inc. - Ordinary Shares (Sub Voting)

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.16
Prev Close	$1.21
Open	$1.16
Dividend Yield	0.00%
50-Day Moving Average	$1.24
Beta	1.05
Avg. Volume	821,397.57
PE Ratio	-8.91

52-Week High	$1.62
52-Week Low	$0.4256
Market Capitalization	$755.18M
EPS (Annual)	-$0.2155
Price to Book	0.93
Revenue Per Employee	$249,773.45
Enterprise Value/EBITDA	N/A

CRLBF
Cresco Labs Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRLBF News

CRLBFCresco Labs Inc